



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

Ref: ADL/SE/2026-27/26
July 29, 2026

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

BSE CODE – 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Bandra - Kurla Complex,
Bandra (E), Mumbai – 400051

NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: Intimation of Conference Call

This is to inform you that Quarterly Earning Conference Call for the Investors and Analysts have been scheduled on **Monday, August 3, 2026 at 11:00 A.M. IST** to discuss the Company's financial performance for the Quarter ended June 30, 2026.

Please find attached herewith invitation for the same.

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M.No.: F12932

Q1 FY27 Earnings Conference Call



3rd August 2026 (Monday)



11:00 AM, IST

(HK/Singapore 1:30 PM, UK 6:30 AM, USA 1:30 AM EST)

PARTICIPANTS



Mr. Harshit Savla

Jt. Managing Director



Mr. Harit Shah

Whole time Director



Mr. Adhish Patil

Chief Finance Officer & Chief Operating Officer



Mr. Vishwa Savla

Managing Director, Pinnacle Life Science Private Limited

PRE-REGISTRATION LINK

[Click Here](#)

CONFERENCE DIAL-IN DETAILS

India	+91 22 6280 1309 / +91 22 7115 8210
United States	1 866 746 2133
United Kingdom	0 808 101 1573
Singapore	800 101 2045
Hong Kong	800 964 448

RSVP:

Strategic Growth Advisors Pvt. Ltd.

Mr. Deven Dhruva | Ms. Krisha Shrimankar

+ 91 98333 73300 | + 91 87797 99281